Literature DB >> 25487614

Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells.

Hichem Gallala1, Jochen Winter, Nadine Veit, Michael Nowak, Sven Perner, Cornelius Courts, Dominik Kraus, Viktor Janzen, Rainer Probstmeier.   

Abstract

We have recently shown that staurosporine mediates the conversion of small cell lung carcinoma (SCLC) cells into a neuron-like process-bearing phenotype. Here, we have extended these studies to the staurosporine analogs K252a, lestaurtinib, PKC412, stauprimide, and UCN-01 and analyzed their influence on process extension, cell cycle distribution, and induction of polyploidy in four SCLC cell lines. In GLC-2 cells, all compounds provoked extensive process formation with the exception of PKC412 that showed no response. In H1184 cells, process formation was predominantly induced by staurosporine and, to lesser extent, in lestaurtinib-, stauprimide-, and UCN-01-treated cells. In the presence of K252a or PKC412, cells became bipolar and spindle shaped or showed pronounced cell flattening. In GLC-36 and SCLC-24H cells, only cell flattening was detectable. Process formation was reversible upon drug removal as shown for GLC-2 and H1184 cells. Fluorescence-activated cell sorting (FACS) and fluorescence in situ hybridization (FISH) analysis indicated the induction of polyploidy in all staurosporine and in two out of four stauprimide-treated SCLC cell lines. For other staurosporine analogs, polyploidy was observed only in UCN-01-treated GLC-36 cells and in K252a-treated H1184 and GLC-36 cells. The presence of staurosporine or its analogs did not alter the constitutive activation pattern of the canonical Akt/PI3K or MEK/extracellular signal-regulated kinase (ERK)1/2 signaling pathways nor could we detect an influence of stauprimide application on the expression level of the c-Myc oncogene. These data demonstrate that in SCLC cells, albeit a higher substrate specificity, staurosporine analogs can induce staurosporine-comparable effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25487614     DOI: 10.1007/s13277-014-2897-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  36 in total

1.  Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole.

Authors:  T Akiyama; M Shimizu; M Okabe; T Tamaoki; S Akinaga
Journal:  Anticancer Drugs       Date:  1999-01       Impact factor: 2.248

Review 2.  Protein kinase inhibition of clinically important staurosporine analogues.

Authors:  Osman A B S M Gani; Richard A Engh
Journal:  Nat Prod Rep       Date:  2010-03-04       Impact factor: 13.423

3.  A small molecule primes embryonic stem cells for differentiation.

Authors:  Shoutian Zhu; Heiko Wurdak; Jian Wang; Costas A Lyssiotis; Eric C Peters; Charles Y Cho; Xu Wu; Peter G Schultz
Journal:  Cell Stem Cell       Date:  2009-05-08       Impact factor: 24.633

4.  ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.

Authors:  Veit J Scheble; Martin Braun; Rameen Beroukhim; Craig H Mermel; Christian Ruiz; Theresia Wilbertz; Ann-Cathrin Stiedl; Karen Petersen; Markus Reischl; Rainer Kuefer; David Schilling; Falko Fend; Glen Kristiansen; Matthew Meyerson; Mark A Rubin; Lukas Bubendorf; Sven Perner
Journal:  Mod Pathol       Date:  2010-05-14       Impact factor: 7.842

Review 5.  Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.

Authors:  Munira Shabbir; Robert Stuart
Journal:  Expert Opin Investig Drugs       Date:  2010-03       Impact factor: 6.206

Review 6.  Stem cell-like cancer cells in cancer cell lines.

Authors:  Toru Kondo
Journal:  Cancer Biomark       Date:  2007       Impact factor: 4.388

7.  Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy.

Authors:  Pierre-Emmanuel Puig; Marie-Noëlle Guilly; André Bouchot; Nathalie Droin; Dominique Cathelin; Florence Bouyer; Laure Favier; François Ghiringhelli; Guido Kroemer; Eric Solary; François Martin; Bruno Chauffert
Journal:  Cell Biol Int       Date:  2008-05-02       Impact factor: 3.612

8.  CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.

Authors:  Chien-Chih Ke; Ren-Shyan Liu; An-Hang Yang; Ching-Sheng Liu; Chin-Wen Chi; Ling-Ming Tseng; Yi-Fan Tsai; Jennifer H Ho; Chen-Hsen Lee; Oscar K Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-19       Impact factor: 9.236

9.  A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

Authors:  Cynthia X Ma; Matthew J C Ellis; Gina R Petroni; Zhanfang Guo; Shi-Rong Cai; Christine E Ryan; A Craig Lockhart; Michael J Naughton; Timothy J Pluard; Christiana M Brenin; Joel Picus; Allison N Creekmore; Tibu Mwandoro; Erin R Yarde; Jerry Reed; Mark Ebbert; Philip S Bernard; Mark Watson; Laurence A Doyle; Janet Dancey; Helen Piwnica-Worms; Paula M Fracasso
Journal:  Breast Cancer Res Treat       Date:  2012-12-15       Impact factor: 4.872

10.  Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers.

Authors:  Zhanna V Chitikova; Serguei A Gordeev; Tatiana V Bykova; Svetlana G Zubova; Valery A Pospelov; Tatiana V Pospelova
Journal:  Cell Cycle       Date:  2014-03-07       Impact factor: 4.534

View more
  2 in total

1.  Staurosporine Induces the Generation of Polyploid Giant Cancer Cells in Non-Small-Cell Lung Carcinoma A549 Cells.

Authors:  Alexander Glassmann; Carmen Carrillo Garcia; Viktor Janzen; Dominik Kraus; Nadine Veit; Jochen Winter; Rainer Probstmeier
Journal:  Anal Cell Pathol (Amst)       Date:  2018-10-10       Impact factor: 2.916

2.  The Presence of Yin-Yang Effects in the Migration Pattern of Staurosporine-Treated Single versus Collective Breast Carcinoma Cells.

Authors:  Frank A H Meyer; Dominik Kraus; Alexander Glassmann; Nadine Veit; Jochen Winter; Rainer Probstmeier
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.